Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Dr Seth Lederman tells Proactive the clinical-stage biopharmaceutical company has signed a second research collaboration agreement with Massachusetts General Hospital.
Dr Lederman says while the first collaboration is centered on heart transplantation, the second focuses on developing its antibody TNX-1500 to prevent and treat kidney transplant rejection.
Price: 0.91 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tonix Pharmaceuticals named herein, including the promotion by the Company of Tonix Pharmaceuticals in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Dr Seth Lederman tells Proactive the New York-based clinical-stage biopharmaceutical company is 'delighted' as it recently reported positive findings in its Phase 3 RELIEF study to treat fibromyalgia. Dr Lederman says now, the firm will...
Mining
Health
Industry & services
Retail & consumer
Prev article
